C.R. Bard Inc. was denied a fair trial in a $68 million pelvic mesh injury suit when it was prohibited from telling the jury that it was complying with the law when it marketed the devices in question without conducting clinical trials, the New Jersey Supreme Court ruled.

The court, affirming the judgment of the Appellate Division with a modification, remanded the case for a new trial. It concluded that evidence that a medical device can be marketed without first undergoing clinical trials was admissible under the specific circumstances in the case.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]